NCT07160231 (REDO-JAK) is a Phase 4 clinical trial of JAKi dose reduction strategy in Rheumatoid Arthritis (RA), sponsored by Sint Maartenskliniek.

Who is sponsoring NCT07160231?

NCT07160231 is sponsored by Sint Maartenskliniek.

What drugs are being tested in NCT07160231?

Interventions in NCT07160231: JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy.

What condition does NCT07160231 study?

NCT07160231 studies Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (AxSpA).

Is NCT07160231 still recruiting?

NCT07160231 is currently recruiting now. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT07160231: REDO-JAK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

Recruiting now Phase 4 Last updated 17 September 2025

What this trial tests

Phase 4 trial testing JAKi dose reduction strategy in Rheumatoid Arthritis (RA) in 200 participants. Currently enrolling.

Timeline

15 September 2025

Primary endpoint
1 May 2028

1 May 2028

Quick facts

Lead sponsor	Sint Maartenskliniek
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	15 September 2025
Primary completion	1 May 2028
Estimated completion	1 May 2028
Sites	7 locations across Netherlands

Drugs / interventions tested

JAKi dose reduction strategy — full drug profile →
JAKi disease activity guided continuation of same dose strategy — full drug profile →

Conditions studied

Rheumatoid Arthritis (RA) — all drugs for Rheumatoid Arthritis (RA) →
Psoriatic Arthritis (PsA) — all drugs for Psoriatic Arthritis (PsA) →
Axial Spondyloarthritis (AxSpA) — all drugs for Axial Spondyloarthritis (AxSpA) →

Sponsor

Sint Maartenskliniek — full company profile →

Who can join

16 and older, any sex, with Rheumatoid Arthritis (RA) or Psoriatic Arthritis (PsA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who are in a state of low disease activity or remission while on JAKi. The main question it aims to answer is: Is a disease activity guided dose reduction strategy for JAKi not inferior in terms of efficacy compared to disease activity guided JAKi continuation in patients with RA/PsA/axSpA that are currently in a low disease activity/remission state? Researchers will compare a disease activity guided dose reduction strategy for JAKi to disease activity guided JAKi continuation in patients with RA/PsA/axSpA that are currently in a low disease activity/remission state to see if a disease activity guided dose reduction strategy for JAKi is not inferior in terms of efficacy compared to disease activity guided JAKi continuation. Participants will: * Follow a JAKi dose reduction strategy or will continue using JAKi in the same dose * Study (telemonitoring) visits are planned every 3 months * At every visit, patients are asked to complete patient-reported outcomes that assess daily functioning, health-related quality of life, pain, fatigue, productivity loss, medical consumption and medication adherence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis (RA)

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
NCT07264101 — Validity And Reliability Of The Four Square Step Test In Individuals With Rheumatoid Arthritis · recruiting
NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
NCT07100873 — A Phase 1 Study of ADI-001 in Rheumatoid Arthritis · Phase 1 · recruiting

Other Sint Maartenskliniek trials

Trials by the same sponsor.

NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
NCT06259227 — Cardiorespiratory Fitness Training in Patients With Incomplete Spinal Cord Injury · NA · terminated
NCT06214546 — Effect of Different Support Systems on Gait · NA · completed
NCT06516120 — Kinematics of Movements Provoked by an Augmented Reality App · recruiting
NCT06306352 — Vibrotactile Feedback in Exoskeletons · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07160231 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sint Maartenskliniek
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07160231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing